Targeting the sarcomere in inherited cardiomyopathies

• Published in: Nature reviews cardiology 2022-06, Vol.19 (6), p.353-363
• Main Authors: Lehman, Sarah J., Crocini, Claudia, Leinwand, Leslie A.
• Format: Article
• Language: English
• Subjects: 692/699/75/74; 692/700/565/1436; Cardiac Imaging; Cardiac Surgery; Cardiology; Cardiomyopathies - metabolism; Cardiomyopathy; Cardiomyopathy, Dilated - genetics; Cardiomyopathy, Hypertrophic - drug therapy; Cardiomyopathy, Hypertrophic - genetics; Disease; Heart failure; Humans; Medicine; Medicine & Public Health; Musculoskeletal system; Mutation; Myocardium - metabolism; Myosins - genetics; Myosins - metabolism; Pathogenesis; Proteins; Review Article; Sarcomeres - genetics; Sarcomeres - metabolism
• ISSN: 1759-5002; 1759-5010
• DOI: 10.1038/s41569-022-00682-0

Variants in >12 genes encoding sarcomeric proteins can cause various cardiomyopathies. The two most common are hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM). Current therapeutics do not target the root causes of these diseases, but attempt to prevent disease progression and/or to manage symptoms. Accordingly, novel approaches are being developed to treat the cardiac muscle dysfunction directly. Challenges to developing therapeutics for these diseases include the diverse mechanisms of pathogenesis, some of which are still being debated and defined. Four small molecules that modulate the myosin motor protein in the cardiac sarcomere have shown great promise in the settings of HCM and DCM, regardless of the underlying genetic pathogenesis, and similar approaches are being developed to target other components of the sarcomere. In the setting of HCM, mavacamten and aficamten bind to the myosin motor and decrease the ATPase activity of myosin. In the setting of DCM, omecamtiv mecarbil and danicamtiv increase myosin activity in cardiac muscle (but omecamtiv mecarbil decreases myosin activity in vitro). In this Review, we discuss the therapeutic strategies to alter sarcomere contractile activity and summarize the data indicating that targeting one protein in the sarcomere can be effective in treating patients with genetic variants in other sarcomeric proteins, as well as in patients with non-sarcomere-based disease. Variants in genes encoding sarcomeric proteins can cause hypertrophic or dilated cardiomyopathy. In this Review, the authors discuss therapeutic strategies to target the cardiac sarcomere, focusing on four small molecules that have been developed that inhibit or activate the myosin motor protein to decrease or increase contractile force, respectively. Key points Variants in genes encoding sarcomeric proteins are a leading cause of cardiomyopathies that are characterized by protein-specific molecular mechanisms of disease. Sarcomeric proteins can be targeted by small molecules to directly modulate contractile function in cardiac muscle. Small molecules that are targeted to the myosin heavy chain modulate enzymatic activity and/or availability of the myosin motor, leading to an increase or decrease in force production. Small molecules that target the myosin heavy chain, such as mavacamten and aficamten, can act via distinct molecular mechanisms that lead to altered myosin function. Sarcomere pharmacology suggests that small molecules